Back to Report Store Home

Osteoporosis Therapeutics in Asia-Pacific Markets to 2024 – Growth Driven by ongoing Transition from Anti-resorptive Agents to Anabolic Therapies, Rising Prevalence, and Growing Awareness

  • Published: Jul-2018
  • Report Code: GBIHC478MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 8

2 Introduction 10

2.1 Disease Introduction 10

2.2 Epidemiology 10

2.3 Symptoms 11

2.4 Etiology and Pathophysiology 13

2.4.1 Pathophysiology 14

2.5 Diagnosis 15

2.6 Disease Stages 17

2.7 Prognosis 19

2.8 Treatment Guidelines and Options 20

2.8.1 Treatment Guidelines 20

2.8.2 National and Local Registries 21

2.9 Treatment Options 22

2.9.1 Treatment Algorithm 22

2.9.2 Pharmacological Treatments 23

2.9.3 Non-Pharmacological Treatments 25

2.9.4 Exercise 25

2.9.5 Dietary Interventions 25

3 Marketed Products 27

3.1 Overview 27

3.2 Bisphosphonates 28

3.2.1 Risedronate – Warner Chilcott 28

3.2.2 Alendronate – Merck & Co. 29

3.2.3 Boniva (ibandronate) – Roche 30

3.2.4 Zoledronic Acid – Novartis 31

3.2.5 Recalbon/Bonoteo (minodronate) – Ono and Astellas Pharma 33

3.2.6 Etidronate – Procter & Gamble and Sumitomo Pharmaceuticals 33

3.3 Dual-Acting Non-Bisphosphonates 34

3.3.1 Strontium Ranelate – Servier 34

3.4 Selective Estrogen Receptor Modulators 35

3.4.1 Evista (raloxifene) – Eli Lilly 35

3.4.2 Viviant (bazedoxifene) – Ligand and Pfizer 36

3.5 Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Inhibitor 38

3.5.1 Prolia/Pralia (denosumab) – Amgen 38

3.6 Calcitonins 39

3.6.1 Calcitonin-salmon 39

3.7 Parathyroid Hormone 40

3.7.1 Forteo (teriparatide) – Eli Lilly 40

3.8 Vitamin D3 Derivative 42

3.8.1 Edirol (eldecalcitol) – Chugai 42

3.9 Comparative Efficacy and Safety of Marketed Products 42

4 Product Pipeline 46

4.1 Overview 46

4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty 47

4.3 Pipeline Distribution by Molecular Target 49

4.4 Promising Pipeline Candidates 52

4.4.1 Evenity (Romosozumab/AMG-785) – Amgen 52

4.4.2 Tymlos - Abaloparatide-SC – Radius Health 55

4.4.3 Uni-PTH – Uni-Bio Science 58

4.5 Comparative Efficacy and Safety of Pipeline Products 60

4.6 Product Competitiveness Framework 60

5 Clinical Trial Analysis 63

5.1 Failure Rate 63

5.1.1 Overall Failure Rate 63

5.1.2 Failure Rate by Phase and Molecule Type 65

5.1.3 Failure Rate by Phase and Molecular Target 65

5.2 Clinical Trial Duration 66

5.2.1 Clinical Trial Duration by Molecule Type 66

5.2.2 Clinical Trial Duration by Molecular Target 67

5.3 Clinical Trial Size 68

5.3.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 68

5.3.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 71

5.4 Summary of Clinical Trial Metrics 73

6 Multi-Scenario Forecast 74

6.1 Geographical Markets 74

6.2 Asia-Pacific Markets 75

6.3 India 76

6.3.1 Treatment Usage Patterns 76

6.3.2 Annual Cost of Therapy 77

6.3.3 Market Size 78

6.4 China 80

6.4.1 Treatment Usage Patterns 80

6.4.2 Annual Cost of Therapy 82

6.4.3 Market Size 83

6.5 Australia 85

6.5.1 Treatment Usage Patterns 85

6.5.2 Annual Cost of Therapy 85

6.5.3 Market Size 87

6.6 South Korea 89

6.6.1 Treatment Usage Patterns 89

6.6.2 Annual Cost of Therapy 90

6.6.3 Market Size 90

6.7 Japan 92

6.7.1 Treatment Usage Patterns 92

6.7.2 Annual Cost of Therapy 93

6.7.3 Market Size 94

7 Market Dynamics (Drivers and Barriers) of Osteoporosis Therapeutics Market 97

7.1 Drivers 97

7.1.1 Rising Prevalence 97

7.1.2 Increasing Health Insurance Coverage for Aged Population 97

7.1.3 Increasing Public and Policymaker Awareness 97

7.1.4 Promising Late-Stage Pipeline Products can Change the Treatment Paradigm 98

7.2 Barriers 98

7.2.1 Impending Patent Cliffs and Generic Erosion 98

7.2.2 Low Diagnosis and Treatment Rates 99

7.2.3 Non-Availability or Lack of Benefits for Combination Anabolic and Antiresorptive Therapies 99

7.2.4 Competition from Traditional Medicines 99

8 Deals and Strategic Consolidations 100

8.1 Licensing Deals 100

8.1.1 Deals by Region and Value 100

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 101

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 101

8.1.4 Key Licensing Deals 104

8.2 Co-development 106

8.2.1 Deals by Region and Value 106

8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 106

8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 107

8.2.4 Key Co-Development Deals 108

9 Appendix 110

9.1 All Pipeline Drugs by Stage of Development 110

9.1.1 Discovery 110

9.1.2 Preclinical 112

9.1.3 Phase I 115

9.1.4 Phase II 116

9.1.5 Phase III 116

9.1.6 Pre-registration 117

9.2 Summary of Multi-scenario Market Forecasts to 2024 117

9.2.1 Asia-Pacific 117

9.2.2 India 118

9.2.3 China 118

9.2.4 Australia 119

9.2.5 South Korea 119

9.2.6 Japan 120

9.3 Bibliography 120

9.4 Abbreviations 132

9.5 Research Methodology 134

9.5.1 Secondary Research 134

9.5.2 Marketed Product Profiles 135

9.5.3 Late-Stage Pipeline Candidates 135

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 135

9.5.5 Product Competitiveness Framework 135

9.5.6 Pipeline Analysis 136

9.5.7 Clinical Trials 136

9.5.8 Clinical trial Endpoint Analysis 136

9.5.9 Forecasting Model 137

9.5.10 Deals Data Analysis 138

9.6 Contact Us 138

9.7 Disclaimer 138

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards